Outcomes in PSC-IBD patients who have undergone total proctocolectomy with ileal pouch-anal anastomosis (IPAA) vs subtotal colectomy with ileosigmoid or ileorectal anastomosis.
| . | Total Proctocolectomy With Ileal Pouch-Anal Anastomosis (n = 99) . | Subtotal Colectomy With Ileosigmoid Or Ileorectal Anastomosis (n = 26) . |
|---|---|---|
| Primary Outcomes | ||
| Dysplasia | ||
| Location | ||
| Ileal Pouch | 2 (2.0%) | |
| Rectal cuff | 2 (2.0%) | |
| Rectum/Colon | 0 (0%) | |
| Neoplasia | ||
| Location | ||
| Ileal Pouch | 0 (0%) | |
| Rectal cuff | 1 (1.0%) | |
| Rectum/Colon | 0 (0%) | |
| Secondary Outcomes | ||
| Surgical complications | ||
| Number per 100 years | 7.5 | 2.7 |
| Inflammatory Complications | ||
| Pouchitis or Colitis | 87 (87.9%) | 16 (61.5%) |
| Type of Pouchitis | ||
| AARP | 12 (14.8%) | |
| CADP | 15 (17.9%) | |
| CARP | 41 (48.8%) | |
| Crohn’s-like disease of pouch | 19 (21.8%) | |
| C. difficile pouchitis | 23 (23.2%) | |
| Score for inflammation | ||
| PDAI, median (range) | 7 (0-12) | |
| Endoscopic score, median (range) | 3 (0-6) | |
| Prepouch inflammation | 36 (43.4%) | |
| Mayo Score for UC (n = 3) | ||
| 1 (mild) | 1 (33.3%) | |
| 2 (moderate) | 1 (33.3%) | |
| 3 (severe) | 1 (33.3%) | |
| SES-CD (n = 13) | ||
| 0-6 (inactive/mild) | 6 (46.2%) | |
| >6 (moderate/severe) | 7 (53.8%) | |
| Treatment (multiple) | ||
| Antibiotics | 84 (96.6%) | 3 (18.8%) |
| Probiotics | 35 (40.2%) | 0 (0%) |
| Mesalamine | 33 (37.9%) | 5 (31.3%) |
| Budesonide | 36 (41.4%) | 4 (25.0%) |
| Prednisone | 45 (51.7%) | 5 (31.3%) |
| Biologics | 16 (18.4%) | 8 (50.0%) |
| Small molecules | 0 (0%) | 0 (0%) |
| Functional Complications | ||
| Pouch dyssynergia | 14 (14.1%) | |
| . | Total Proctocolectomy With Ileal Pouch-Anal Anastomosis (n = 99) . | Subtotal Colectomy With Ileosigmoid Or Ileorectal Anastomosis (n = 26) . |
|---|---|---|
| Primary Outcomes | ||
| Dysplasia | ||
| Location | ||
| Ileal Pouch | 2 (2.0%) | |
| Rectal cuff | 2 (2.0%) | |
| Rectum/Colon | 0 (0%) | |
| Neoplasia | ||
| Location | ||
| Ileal Pouch | 0 (0%) | |
| Rectal cuff | 1 (1.0%) | |
| Rectum/Colon | 0 (0%) | |
| Secondary Outcomes | ||
| Surgical complications | ||
| Number per 100 years | 7.5 | 2.7 |
| Inflammatory Complications | ||
| Pouchitis or Colitis | 87 (87.9%) | 16 (61.5%) |
| Type of Pouchitis | ||
| AARP | 12 (14.8%) | |
| CADP | 15 (17.9%) | |
| CARP | 41 (48.8%) | |
| Crohn’s-like disease of pouch | 19 (21.8%) | |
| C. difficile pouchitis | 23 (23.2%) | |
| Score for inflammation | ||
| PDAI, median (range) | 7 (0-12) | |
| Endoscopic score, median (range) | 3 (0-6) | |
| Prepouch inflammation | 36 (43.4%) | |
| Mayo Score for UC (n = 3) | ||
| 1 (mild) | 1 (33.3%) | |
| 2 (moderate) | 1 (33.3%) | |
| 3 (severe) | 1 (33.3%) | |
| SES-CD (n = 13) | ||
| 0-6 (inactive/mild) | 6 (46.2%) | |
| >6 (moderate/severe) | 7 (53.8%) | |
| Treatment (multiple) | ||
| Antibiotics | 84 (96.6%) | 3 (18.8%) |
| Probiotics | 35 (40.2%) | 0 (0%) |
| Mesalamine | 33 (37.9%) | 5 (31.3%) |
| Budesonide | 36 (41.4%) | 4 (25.0%) |
| Prednisone | 45 (51.7%) | 5 (31.3%) |
| Biologics | 16 (18.4%) | 8 (50.0%) |
| Small molecules | 0 (0%) | 0 (0%) |
| Functional Complications | ||
| Pouch dyssynergia | 14 (14.1%) | |
Abbreviations: PSC-IBD, primary sclerosing cholangitis and inflammatory bowel disease; AARP, acute antibiotic-responsive pouchitis; CADP, chronic antibiotic-dependent pouchitis; CARP, chronic antibiotic-refractory pouchitis; PDAI, Pouch Disease Activity Index; UC, ulcerative colitis; SES-CD, Simple endoscopic score for Crohn’s disease.
Outcomes in PSC-IBD patients who have undergone total proctocolectomy with ileal pouch-anal anastomosis (IPAA) vs subtotal colectomy with ileosigmoid or ileorectal anastomosis.
| . | Total Proctocolectomy With Ileal Pouch-Anal Anastomosis (n = 99) . | Subtotal Colectomy With Ileosigmoid Or Ileorectal Anastomosis (n = 26) . |
|---|---|---|
| Primary Outcomes | ||
| Dysplasia | ||
| Location | ||
| Ileal Pouch | 2 (2.0%) | |
| Rectal cuff | 2 (2.0%) | |
| Rectum/Colon | 0 (0%) | |
| Neoplasia | ||
| Location | ||
| Ileal Pouch | 0 (0%) | |
| Rectal cuff | 1 (1.0%) | |
| Rectum/Colon | 0 (0%) | |
| Secondary Outcomes | ||
| Surgical complications | ||
| Number per 100 years | 7.5 | 2.7 |
| Inflammatory Complications | ||
| Pouchitis or Colitis | 87 (87.9%) | 16 (61.5%) |
| Type of Pouchitis | ||
| AARP | 12 (14.8%) | |
| CADP | 15 (17.9%) | |
| CARP | 41 (48.8%) | |
| Crohn’s-like disease of pouch | 19 (21.8%) | |
| C. difficile pouchitis | 23 (23.2%) | |
| Score for inflammation | ||
| PDAI, median (range) | 7 (0-12) | |
| Endoscopic score, median (range) | 3 (0-6) | |
| Prepouch inflammation | 36 (43.4%) | |
| Mayo Score for UC (n = 3) | ||
| 1 (mild) | 1 (33.3%) | |
| 2 (moderate) | 1 (33.3%) | |
| 3 (severe) | 1 (33.3%) | |
| SES-CD (n = 13) | ||
| 0-6 (inactive/mild) | 6 (46.2%) | |
| >6 (moderate/severe) | 7 (53.8%) | |
| Treatment (multiple) | ||
| Antibiotics | 84 (96.6%) | 3 (18.8%) |
| Probiotics | 35 (40.2%) | 0 (0%) |
| Mesalamine | 33 (37.9%) | 5 (31.3%) |
| Budesonide | 36 (41.4%) | 4 (25.0%) |
| Prednisone | 45 (51.7%) | 5 (31.3%) |
| Biologics | 16 (18.4%) | 8 (50.0%) |
| Small molecules | 0 (0%) | 0 (0%) |
| Functional Complications | ||
| Pouch dyssynergia | 14 (14.1%) | |
| . | Total Proctocolectomy With Ileal Pouch-Anal Anastomosis (n = 99) . | Subtotal Colectomy With Ileosigmoid Or Ileorectal Anastomosis (n = 26) . |
|---|---|---|
| Primary Outcomes | ||
| Dysplasia | ||
| Location | ||
| Ileal Pouch | 2 (2.0%) | |
| Rectal cuff | 2 (2.0%) | |
| Rectum/Colon | 0 (0%) | |
| Neoplasia | ||
| Location | ||
| Ileal Pouch | 0 (0%) | |
| Rectal cuff | 1 (1.0%) | |
| Rectum/Colon | 0 (0%) | |
| Secondary Outcomes | ||
| Surgical complications | ||
| Number per 100 years | 7.5 | 2.7 |
| Inflammatory Complications | ||
| Pouchitis or Colitis | 87 (87.9%) | 16 (61.5%) |
| Type of Pouchitis | ||
| AARP | 12 (14.8%) | |
| CADP | 15 (17.9%) | |
| CARP | 41 (48.8%) | |
| Crohn’s-like disease of pouch | 19 (21.8%) | |
| C. difficile pouchitis | 23 (23.2%) | |
| Score for inflammation | ||
| PDAI, median (range) | 7 (0-12) | |
| Endoscopic score, median (range) | 3 (0-6) | |
| Prepouch inflammation | 36 (43.4%) | |
| Mayo Score for UC (n = 3) | ||
| 1 (mild) | 1 (33.3%) | |
| 2 (moderate) | 1 (33.3%) | |
| 3 (severe) | 1 (33.3%) | |
| SES-CD (n = 13) | ||
| 0-6 (inactive/mild) | 6 (46.2%) | |
| >6 (moderate/severe) | 7 (53.8%) | |
| Treatment (multiple) | ||
| Antibiotics | 84 (96.6%) | 3 (18.8%) |
| Probiotics | 35 (40.2%) | 0 (0%) |
| Mesalamine | 33 (37.9%) | 5 (31.3%) |
| Budesonide | 36 (41.4%) | 4 (25.0%) |
| Prednisone | 45 (51.7%) | 5 (31.3%) |
| Biologics | 16 (18.4%) | 8 (50.0%) |
| Small molecules | 0 (0%) | 0 (0%) |
| Functional Complications | ||
| Pouch dyssynergia | 14 (14.1%) | |
Abbreviations: PSC-IBD, primary sclerosing cholangitis and inflammatory bowel disease; AARP, acute antibiotic-responsive pouchitis; CADP, chronic antibiotic-dependent pouchitis; CARP, chronic antibiotic-refractory pouchitis; PDAI, Pouch Disease Activity Index; UC, ulcerative colitis; SES-CD, Simple endoscopic score for Crohn’s disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
